Gastroesophageal RefluxNCT04355455
Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers
A study testing Citalopram in people with Gastroesophageal Reflux, run by Universitaire Ziekenhuizen KU Leuven.
Trial summary
To investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on esophageal sensitivity. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Gastroesophageal Reflux
- What is being tested?
- Citalopram
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14 participants
- Where
- No sites listed yet
- Study dates
- Jul 2011to Jan 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- HV aged between 18 - 60 years
Who cannot join
- history of psychiatric disease or a positive first degree psychiatric family history
- pregnancy or lactation
- concomitant administration of any centrally activating medication (anti-depressive medication, hypnotics, sedatives, anxiolytics, …)
- medication affecting esophageal motility
- significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary, endocrine, autoimmune, renal and hepatic)
- prior history of esophageal, gastric surgery or endoscopic anti-reflux procedure
- history of gastrointestinal disease
About this study
To investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on esophageal sensitivity.
- Conditions
- Gastroesophageal Reflux
- Being tested
- Citalopram, Placebo
- Medical subject headings
- Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CitalopramDrug
40 mg citalopram intravenously
PlaceboDrug
Saline solution
| Study group | Role | What they receive |
|---|---|---|
| Citalopram | Active comparator | Administration of citalopram to assess the esophageal sensitivity in HV Receives: Drug: Citalopram |
| Placebo | Placebo comparator | Administration of placebo to assess the esophageal sensitivity in HV Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in sensitivity to thermal stimulation
To detect changes in thermal stimulation for sensitivity
Measured: After 1 hour 30 minutes after administration citalopram, we will start with the thermal stimulation
Secondary outcomes (5)
Change in sensitivity to mechanical stimulation
To detect changes in mechanical stimulation for sensitivity
Measured: After 1 hour 45 minutes after administration citalopram, we will start with the mechanical stimulation
Change in sensitivity to electrical stimulation
To detect changes in electrical stimulation for sensitivity
Measured: After 2 hours after administration citalopram, we will start with the electrical stimulation
Change in sensitivity to chemical stimulation
To detect changes in chemical stimulation for sensitivity
Measured: After 2 hours 15 minutes after administration citalopram, we will start with the chemical stimulation
Change in positive and negative affect score
To detect change in affect of the multimodal stimulation using the PANAS = Positive and Negative Affect scale that consists of two 10-item scales to measure both positive and negative affect. Higher score on the Positive scale is better; Higher score on the Negative Affect scale is worse.
Measured: At the beginning of the study and at the end of the multimodal stimulation
Change in state trait and anxiety score
to detect changes in the score due to the multimodal stimulation using the The State-Trait Anxiety Inventory (STAI). Each type of anxiety has its own scale of 20 different questions that are scored.Scores range from 20 to 80, with higher scores correlating with greater anxiety.
Measured: At the beginning of the study and at the end of the multimodal stimulation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2020
- Study startJul 2011
- Primary completionDec 2011
- Study completionJan 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastroesophageal RefluxStudies of the same condition, open and under way.
- More trials run by Universitaire Ziekenhuizen KU LeuvenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof Dr Jan Tack, Universitaire Ziekenhuizen KU Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04355455
- Sponsor's protocol ID
- Citalopram MuMoS HV
- Status last verified
- Apr 2020
- First submitted
- 15 Apr 2020
- Last updated
- 21 Apr 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT04355455
- Acronym / sponsor ID
- Citalopram MuMoS HV
- Conditions
- Gastroesophageal Reflux
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenUniversity, hospital or other
- Study start
- Jul 2011 (actual)
- Primary completion
- Dec 2011 (actual)
- Study completion
- Jan 2012 (actual)
- First posted
- 21 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on esophageal sensitivity.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Citalopram | Active comparator | Drug: CitalopramAdministration of citalopram to assess the esophageal sensitivity in HV |
| Placebo | Placebo comparator | Drug: PlaceboAdministration of placebo to assess the esophageal sensitivity in HV |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- HV aged between 18 - 60 years
Key exclusion criteria (7 listed)
- history of psychiatric disease or a positive first degree psychiatric family history
- pregnancy or lactation
- concomitant administration of any centrally activating medication (anti-depressive medication, hypnotics, sedatives, anxiolytics, …)
- medication affecting esophageal motility
- significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary, endocrine, autoimmune, renal and hepatic)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Citalopram40 mg citalopram intravenously | Drug | Citalopram |
| PlaceboSaline solution | Drug | Placebo |
Primary outcome
Change in sensitivity to thermal stimulation
Time frame: After 1 hour 30 minutes after administration citalopram, we will start with the thermal stimulation
To detect changes in thermal stimulation for sensitivity
5 secondary outcomes
Change in sensitivity to mechanical stimulation
Time frame: After 1 hour 45 minutes after administration citalopram, we will start with the mechanical stimulation
Change in sensitivity to electrical stimulation
Time frame: After 2 hours after administration citalopram, we will start with the electrical stimulation
Change in sensitivity to chemical stimulation
Time frame: After 2 hours 15 minutes after administration citalopram, we will start with the chemical stimulation
Change in positive and negative affect score
Time frame: At the beginning of the study and at the end of the multimodal stimulation
Change in state trait and anxiety score
Time frame: At the beginning of the study and at the end of the multimodal stimulation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2020.
- Individual participant dataSharing planned: No
Related trials for Gastroesophageal Reflux
RecruitingObservational study
A Study to Evaluate the Efficacy and Safety of Long-term Administration of K-CAB Tab./K-CAB ODT(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD
Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD)
Active, not recruitingObservational study
RETHINK REFLUX Registry
Gastroesophageal Reflux
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Mitral Regurgitation
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Recruiting
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
Paraesophageal Hernia, GERD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Citalopram in people with Gastroesophageal Reflux, run by Universitaire Ziekenhuizen KU Leuven.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in sensitivity to thermal stimulation (time frame: After 1 hour 30 minutes after administration citalopram, we will start with the thermal stimulation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2020.